Vanda Pharmaceuticals Inc. (VNDA) stock
VNDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3055% below fair value
$3.81+0.00 (0.00%)
Close on Nov 17, 2026Market cap $230.39MP/E –Yield –
Vanda Pharmaceuticals profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Vanda Pharmaceuticals's profit margin for the twelve months ending Sep 30, 2026 was -119.9%. For fiscal 2025 it was -102.0%, against -9.5% the year before. The highest annual figure on record is 50.9% in fiscal 2019.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -102.0% | −92.5 |
| FY2024 | Dec 31, 2024 | -9.5% | −10.8 |
| FY2023 | Dec 31, 2023 | 1.3% | −1.2 |
| FY2022 | Dec 31, 2022 | 2.5% | −9.9 |
| FY2021 | Dec 31, 2021 | 12.3% | +2.9 |
| FY2020 | Dec 31, 2020 | 9.4% | −41.5 |
| FY2019 | Dec 31, 2019 | 50.9% | +37.8 |
| FY2018 | Dec 31, 2018 | 13.1% | +22.5 |
| FY2017 | Dec 31, 2017 | -9.4% | +2.9 |
| FY2016 | Dec 31, 2016 | -12.3% | +23.9 |
| FY2015 | Dec 31, 2015 | -36.3% | −76.5 |
| FY2014 | Dec 31, 2014 | 40.2% | +102.4 |
| FY2013 | Dec 31, 2013 | -62.1% | +25.3 |
| FY2012 | Dec 31, 2012 | -87.4% | −56.1 |
| FY2011 | Dec 31, 2011 | -31.3% | −51.5 |
| FY2010 | Dec 31, 2010 | 20.1% | +808.6 |
| FY2009 | Dec 31, 2009 | -788.5% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -32.3% | +7.8 |
| Q2 FY2026 | Jun 30, 2026 | -123.7% | −72.0 |
| Q1 FY2026 | Mar 31, 2026 | -93.9% | −35.0 |
| Q4 FY2025 | Dec 31, 2025 | -246.8% | −237.5 |
| Q3 FY2025 | Sep 30, 2025 | -40.1% | −29.0 |
| Q2 FY2025 | Jun 30, 2025 | -51.7% | −42.8 |
| Q1 FY2025 | Mar 31, 2025 | -58.9% | −50.2 |
| Q4 FY2024 | Dec 31, 2024 | -9.2% | −3.9 |
| Q3 FY2024 | Sep 30, 2024 | -11.2% | −11.5 |
| Q2 FY2024 | Jun 30, 2024 | -9.0% | −12.3 |
| Q1 FY2024 | Mar 31, 2024 | -8.7% | −13.9 |
| Q4 FY2023 | Dec 31, 2023 | -5.3% | −15.9 |
| Q3 FY2023 | Sep 30, 2023 | 0.4% | −4.7 |
| Q2 FY2023 | Jun 30, 2023 | 3.3% | −0.7 |
| Q1 FY2023 | Mar 31, 2023 | 5.2% | +15.9 |
| Q4 FY2022 | Dec 31, 2022 | 10.6% | +0.2 |
| Q3 FY2022 | Sep 30, 2022 | 5.0% | −6.1 |
| Q2 FY2022 | Jun 30, 2022 | 4.0% | −10.2 |
| Q1 FY2022 | Mar 31, 2022 | -10.7% | −24.5 |
| Q4 FY2021 | Dec 31, 2021 | 10.4% | −1.7 |
| Q3 FY2021 | Sep 30, 2021 | 11.1% | +1.2 |
| Q2 FY2021 | Jun 30, 2021 | 14.2% | +0.2 |
| Q1 FY2021 | Mar 31, 2021 | 13.8% | +13.0 |
| Q4 FY2020 | Dec 31, 2020 | 12.1% | +5.2 |
| Q3 FY2020 | Sep 30, 2020 | 9.9% | −159.0 |
| Q2 FY2020 | Jun 30, 2020 | 14.0% | −5.5 |
| Q1 FY2020 | Mar 31, 2020 | 0.8% | +2.1 |
| Q4 FY2019 | Dec 31, 2019 | 6.9% | −12.6 |
| Q3 FY2019 | Sep 30, 2019 | 168.8% | +154.2 |
| Q2 FY2019 | Jun 30, 2019 | 19.5% | +9.8 |
| Q1 FY2019 | Mar 31, 2019 | -1.3% | −8.3 |
| Q4 FY2018 | Dec 31, 2018 | 19.5% | +23.7 |
| Q3 FY2018 | Sep 30, 2018 | 14.6% | +25.6 |
| Q2 FY2018 | Jun 30, 2018 | 9.7% | +13.4 |
| Q1 FY2018 | Mar 31, 2018 | 7.0% | +27.5 |
| Q4 FY2017 | Dec 31, 2017 | -4.2% | −2.6 |
| Q3 FY2017 | Sep 30, 2017 | -11.0% | – |
| Q2 FY2017 | Jun 30, 2017 | -3.6% | – |
| Q1 FY2017 | Mar 31, 2017 | -20.4% | – |
| Q4 FY2016 | Dec 31, 2016 | -1.6% | – |
See a number that looks wrong?